Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Niraparib for the treatment of ovarian cancer.

Expert opinion on pharmacotherapy - 1 Apr 2017

Kanjanapan Yada, Lheureux Stephanie, Oza Amit M

Abstract excerpt

INTRODUCTION: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are being developed in maintenance and recurrence treatment settings in ovarian cancer. They inhibit single-stranded DNA repair, inducing synthetic lethality in cells with underlying homologous recombination deficiency (HRD). Marked responses are seen in ovarian cancers with breast cancer gene 1 (BRCA1) or 2 (BRCA2) mutation, although...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Ovarian Neoplasms

Share to Piperidines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 28299955
DOI: 10.1080/14656566.2017.1297423

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Niraparib for the treatment of ovarian cancer.PMID 28299955Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

The role of niraparib for the treatment of ovarian cancer.Semantic proximity Read ↗

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity Read ↗

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read ↗

Niraparib in ovarian cancer: results to date and clinical potentialSemantic proximity Read ↗

Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”Semantic proximity Read ↗

PARP Inhibitors in Ovarian CancerSemantic proximity Read ↗

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read ↗

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian CancerSemantic proximity Read ↗

PARP inhibitors in ovarian cancer.Semantic proximity Read ↗

PARP inhibitors in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.